Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 01/08/2024

    Targeted therapy for cancer of unknown primary (Cup)

    Encouraging results from a large international study led by Heidelberg have recently been published in the journal “Lancet”: The genetic material of cancer cells with unknown tissue of origin contains numerous targets for specific drugs that are already available and have been developed to treat other forms of cancer. These suppressed the disease in CUP patients for significantly longer than chemotherapy.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/targeted-therapy-cancer-unknown-primary-cup
  • Research association - 24/07/2024 Graphic in which the various thematic lines of the performance centre are shown in a circle using symbols, e.g. the health thematic line as a heart with a graph of an ECG measurement.

    SPI-MP: pioneer in personalised medical technology

    Every person is unique – even when they are ill. This is why many approaches to personalised medicine have been under development. The Stuttgart Partnership Initiative - Mass Personalization (SPI-MP), which focuses on basic research into fabrication and biomaterial technologies for personalised biomedical systems, is at the heart of such research work. The projects range from artificial knee joint cartilage to state-of-the-art stroke diagnostics.

    https://biopro-v9-test-gi.xanium.io/en/article/news/spi-mp-pioneer-personalised-medical-technology
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://biopro-v9-test-gi.xanium.io/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
  • Press release - 04/07/2024

    Antibody can improve immune cell therapy against leukemia

    Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
  • Press release - 24/06/2024

    Trustworthy AI Made in Mannheim

    How can we use artificial intelligence (AI) to make comprehensible medical decisions? A new project at the University of Mannheim, which has received funding from the Federal Ministry of Education and Research (BMBF), will analyze this question.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/trustworthy-ai-made-mannheim
  • Press release - 13/06/2024

    Position of the cell nucleus affects epigenetics and therefore gene activity and cell function

    Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
  • Press release - 12/06/2024

    Pathogen identification — next-generation sequencing optimizes diagnostics

    Invasive infections such as sepsis require immediate and targeted treatment. Experts from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB and group partners have succeeded in establishing a reconceptualized detection principle that can make a crucial contribution to saving lives through fast, ultra-accurate pathogen identification. They have been chosen to receive the 2024 Stifterverband Science Prize for their efforts.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/pathogen-identification-next-generation-sequencing-optimizes-diagnostics
  • Press release - 07/06/2024

    German Research Foundation honors researchers for animal testing alternatives

    Prof. Dr. Peter Loskill and Dr. Silke Riegger from the 3R Center Tübingen for in-vitro models and animal testing alternatives have been awarded the Ursula M. Händel Animal Welfare Prize 2024. The prize, endowed with 80,000 euros, was awarded to them in Würzburg for the development of organ-on-chip (OoC) systems as an alternative to animal testing.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/german-research-foundation-honors-researchers-animal-testing-alternatives
  • Press release - 23/05/2024

    "They heal wounds, allow bones to grow and calm inflammation" MWK funds cell therapy research into mesenchymal stromal cells with 600,000 euros

    The Baden-Württemberg Ministry of Science, Research and Arts (MWK) is supporting medical researchers at Ulm University with start-up funding totalling 600,000 euros. The aim is to establish an EU consortium for the broad therapeutic use of mesenchymal stromal cells. The funding is being awarded as part of the "BEGIN - Participation in major European projects and initiatives" programme.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/they-heal-wounds-allow-bones-grow-and-calm-inflammation-mwk-funds-cell-therapy-research-mesenchymal-stromal-cells-600000-euros
  • Press release - 23/05/2024

    Predicting cancer risks on the basis of national health data

    Scientists from the German Cancer Research Center (DKFZ) and the European Bioinformatics Institute EMBL-EBI, Hinxton, UK, are using the Danish health registers to predict individual risks for 20 different types of cancer with a high degree of accuracy. The prediction model can also be transferred to other healthcare systems.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/predicting-cancer-risks-basis-national-health-data
  • Innovation in emergency medicine - 23/05/2024 Three men in white coats stand behind a mobile stand equipped with several small devices.

    CARL pushes back the boundaries of resuscitation therapy

    Few people survive a cardiac arrest; blood stops flowing to the brain and other vital organs and the resulting lack of oxygen causes extensive damage to the body. In response to this, researchers at the University Medical Centre Freiburg and Resuscitec GmbH have developed CARL, an innovative resuscitation system, which – in addition to the oxygen level – adjusts numerous blood parameters to individual patient requirements. This greatly improves…

    https://biopro-v9-test-gi.xanium.io/en/article/news/carl-pushes-back-boundaries-resuscitation-therapy
  • Press release - 15/05/2024

    Tumour tissue on a chip: new possibilities for cell therapies and personalized medicine

    How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them. Researchers have now made this very observation possible for the CAR-T cell therapy. This allows us to individually investigate how exactly these tumor cells react to the planned therapy.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/tumour-tissue-chip-new-possibilities-cell-therapies-and-personalized-medicine
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
  • Press release - 03/05/2024

    Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

    Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
  • Press release - 25/04/2024

    Diamond dust shines bright in Magnetic Resonance Imaging

    An unexpected discovery surprised a scientist at the Max Planck Institute for Intelligent Systems in Stuttgart: nanometer-sized diamond particles, which were intended for a completely different purpose, shone brightly in a magnetic resonance imaging experiment – much brighter than the actual contrast agent, the heavy metal gadolinium. Could diamond dust one day become a novel contrast agent used for MRI?

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/diamond-dust-shines-bright-magnetic-resonance-imaging
  • Press release - 19/04/2024

    Electrified bacteria

    PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/bakterien-unter-strom
  • Press release - 17/04/2024

    Cell Biology: Molecular Code Stimulates Pioneer Cells to Build Blood Vessels in the Body

    Cardiovascular diseases, including stroke and myocardial infarction, are the world's leading causes of mortality, accounting for over 18 million deaths a year. A team of KIT researchers has now identified a new cell type in blood vessels responsible for vascular growth. This discovery may allow for novel therapeutic strategies to treat ischemic cardiovascular diseases, i.e. diseases that are caused by reduced or absent blood flow.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/zellbiologie-molekularer-code-regt-pionierzellen-zum-aufbau-von-blutgefaessen-im-koerper
  • Press release - 11/04/2024

    How the body switches out of “fight” mode Study in Nature unlocks how cortisone inhibits inflammation

    Cortisone and other related glucocorticoids are extremely effective at curbing excessive immune reactions. But previously, astonishingly little was known about how they exactly do that. A team of researchers from Charité – Universitätsmedizin Berlin, Uniklinikum Erlangen and Ulm University have now explored the molecular mechanism of action in greater detail.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/wie-der-kampfmodus-im-koerper-beendet-wird-studie-nature-entschluesselt-wie-kortison-entzuendungen-daempft
  • Press release - 10/04/2024

    Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform

    With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
  • Press release - 02/04/2024

    Precise localization of miniature robots and surgical instruments inside the body

    In the medicine of the future, tiny robots will navigate independently through tissue and medical instruments will indicate their position inside the body during surgery. Both require doctors to be able to localize and control the devices precisely and in real time. Scientists from the German Cancer Research Center (DKFZ) have now described a signaling method based on an oscillating magnet that can significantly improve such medical applications.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/precise-localization-miniature-robots-and-surgical-instruments-inside-body
  • Press release - 13/03/2024

    Diabetes: New technology opens up improved opportunities for research

    More than seven million people in Germany suffer from diabetes. At the same time, research into drugs to treat this widespread disease is still difficult. Scientists led by Prof. Dr. Peter Loskill from the NMI Natural and Medical Sciences Institute and the Faculty of Medicine of the Eberhard Karls University of Tübingen have now developed a technique that significantly improves the view at the molecular and cell biological level in the pancreas.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/diabetes-new-technology-opens-improved-opportunities-research
  • Press release - 04/03/2024

    First Step Toward Early Diagnosis of Metastasis

    Team involving the University of Freiburg has developed a new analytical method for the basement membrane in human lungs.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/first-step-toward-early-diagnosis-metastasis
  • Press release - 01/03/2024

    Using Data to Improve Understanding of Relationships between Proteins and Diseases

    Working with a new Emmy Noether Group, Dr. Pascal Schlosser is investigating how machine learning can aid in understanding the complex relationships between genes, proteins, and diseases.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/using-data-improve-understanding-relationships-between-proteins-and-diseases
  • Press release - 02/02/2024

    Epigenetic status determines metastasis

    Scientists from the German Cancer Research Center (DKFZ) and Medical Faculty Mannheim of the Heidelberg University investigated in mice how spreading tumor cells behave at the site of metastasis: Some tumor cells immediately start to form metastases. Others leave the blood vessel and may then enter a long period of dormancy. What determines which path the cancer cells take is their epigenetic status.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/epigenetischer-status-entscheidet-ueber-metastasierung
  • Press release - 04/01/2024

    Key player in viral heart inflammation discovered

    Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/key-player-viral-heart-inflammation-discovered

Page 1 / 6

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search